Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Japanese centre licenses Vivalis technology

This article was originally published in Scrip

Executive Summary

Kaketsuken, Japan's Chemo-Sero Therapeutic Research Institute, has signed two commercial licences giving it access to Vivalis's EB66 technology for the production of vaccines. The deal covers both the human and veterinary fields, including Vaccinia virus-based recombinant and live/inactivated vaccines for human use. The French firm's EB66 duck embryonic stem cell-derived line can be used to replace traditional egg-based methods, with benefits including good genetic stability and easy scale-up, Vivalis says. Although detailed financial terms were not disclosed, the company will receive up front, milestone and sales royalty payments as part of the tie-up. Kaketsuken is run as an independent foundation but has strong links to government-run programmes.



Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts